Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for "late-onset" hypogonadism: A case report.

Testosterone therapy cardiometabolic risk factors obesity type 2 diabetes “late-onset” hypogonadism

Journal

SAGE open medical case reports
ISSN: 2050-313X
Titre abrégé: SAGE Open Med Case Rep
Pays: England
ID NLM: 101638686

Informations de publication

Date de publication:
2019
Historique:
received: 15 03 2018
accepted: 14 12 2018
entrez: 6 2 2019
pubmed: 6 2 2019
medline: 6 2 2019
Statut: epublish

Résumé

For obese type 2 diabetes patients, weight reduction is one of the most important measures but fails in most cases. Testosterone deficiency can be the reason for such failure. This case presents a 57-year-old man who was referred to a urologist due to benign prostatic hyperplasia and erectile dysfunction. He had type 2 diabetes, was overweight, and had hypertension and dyslipidemia. The blood test revealed testosterone deficiency. Under testosterone therapy, the patient lost 10 kg; cardiometabolic parameters returned to normal and lower urinary tract symptoms disappeared; complete remission of diabetes was recorded. Overweight and obese patients with type 2 diabetes should be tested for hypogonadism and testosterone therapy, if indicated, be considered. These patients can considerably benefit from testosterone therapy in terms of sustainable weight loss and a clinically significant reduction of cardiometabolic risk factors including complete remission of diabetes.

Identifiants

pubmed: 30719309
doi: 10.1177/2050313X18823454
pii: 10.1177_2050313X18823454
pmc: PMC6349975
doi:

Types de publication

Case Reports

Langues

eng

Pagination

2050313X18823454

Déclaration de conflit d'intérêts

Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: A.H. has received partial funding for a registry study and travel grants from Bayer AG; K.H. has received travel grants from Bayer AG; F.S. is a full-time employee of Bayer AG.

Références

Obes Rev. 2000 Oct;1(2):57-9
pubmed: 12119987
Health Qual Life Outcomes. 2003 May 01;1:15
pubmed: 12747807
Int J Clin Pract. 2006 Jul;60(7):762-9
pubmed: 16846397
J Clin Endocrinol Metab. 2010 Jun;95(6):2536-59
pubmed: 20525905
J Clin Endocrinol Metab. 2011 Sep;96(9):2898-903
pubmed: 21778224
Obes Surg. 2012 Dec;22(12):1835-42
pubmed: 22923309
JAMA Surg. 2014 Mar;149(3):275-87
pubmed: 24352617
Int J Endocrinol. 2014;2014:527470
pubmed: 24688542
Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):313-22
pubmed: 25105998
Diabetes Care. 2014 Dec;37(12):3188-95
pubmed: 25231895
Diabetologia. 2015 Jul;58(7):1448-53
pubmed: 25924987
Int J Obes (Lond). 2016 Jan;40(1):162-70
pubmed: 26219417
Diabetes Care. 2016 Jan;39(1):82-91
pubmed: 26622051
Endocr Pract. 2016 Jul;22 Suppl 3:1-203
pubmed: 27219496
BMJ. 2017 Sep 13;358:j4030
pubmed: 28903916
Endocrinol Diabetes Metab Case Rep. 2017 Sep 04;2017:null
pubmed: 28924480
J Cachexia Sarcopenia Muscle. 2018 Jun;9(3):465-481
pubmed: 29542875

Auteurs

Ahmad Haider (A)

Private Urology Practice, Bremerhaven, Germany.

Karim Haider (K)

Private Urology Practice, Bremerhaven, Germany.

Farid Saad (F)

Global Medical Affairs Andrology, Bayer AG, Berlin, Germany.
Gulf Medical University, School of Medicine, Ajman, UAE.

Markolf Hanefeld (M)

Studienzentrum Metabolisch-Vaskuläre Medizin, GWT-TUD GmbH, Dresden, Germany.

Classifications MeSH